Drug Database
Back to search

France· FR:69565621

PONSTYL 250 mg, gélule

A medicinal product containing acide méfénamique, registered in France by PFIZER HOLDING FRANCE, on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedPONSTYL 250 mg, géluleATC—REGISTER NO.FR:69565621PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about acide méfénamiqueAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ACIDE MÉFÉNAMIQUE
Manufacturer
PFIZER HOLDING FRANCE
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930852446
    2 plaquette(s) PVC aluminium de 10 gélule(s)
    EUR 2.88

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Acide méfénamique in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All acide méfénamique products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Austria · Mefenam, Parkakut
  • Cyprus · Aidol, Alfoxan
  • Spain · Coslan
  • United Kingdom (Northern Ireland) · Contraflam, Mefenamic Acid
  • Greece · Acinic, Aidol
  • Hungary · Ponmel
  • Ireland · Mefac, Ponstan
  • Malta · Alfoxan, Mefac
  • Romania · Vidan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aa91ad50-f688-4d47-80bb-7ea5008f6521
GET /v1/drugs/aa91ad50-f688-4d47-80bb-7ea5008f6521?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69565621",
  "date_amm": "1996-11-29",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "ACIDE MÉFÉNAMIQUE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about acide méfénamique.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console